top of page

Overcoming the drug delivery limitations of current LNP approaches

ttLNP platform.jpg

Our ttLNP Platform

Our research and intellectual property portfolio, licensed from Tufts University and built by our founder Dr. Qiaobing Xu over the last decade, provide a strong foundation to develop an extensive and rapidly growing library of ionizable lipids and LNP leads based on our differentiated ttLNP platform.

Our ttLNP platform enables rational design, high throughput screening and optimization of physical and chemical properties and formulation of lipid nanoparticles with diverse cargoes. The proprietary chemistry associated with the creation of ionizable lipids is a key differentiator of Hopewell, and pre-clinical research conducted by Hopewell and industry partners, including in rodents and non-human primates (NHP), have demonstrated high translatability for systemic delivery to targeted tissues across species. Based on research to date, we expect our technology to overcome the drug delivery limitations of current LNP approaches in terms of organ, tissue and cell targeting, biocompatibility and sustained high expression with repeat dosing.

Hopewell’s ttLNPs have been shown, through a decade of peer reviewed publications to deliver a variety of high impact genomic cargoes, including mRNA, siRNA, DNA, gene editing and gene-writing apparatus, to organs, tissues and cells throughout the body, with the potential to impact multiple areas of medicine.

We continue to innovate and expand our ttLNP platform to enable a new generation of highly targeted genomic medicines for patients with unmet medical needs.

Key Scientific Publications

Hopewell was established with scientific data featured in over a decade of leading publications that highlight the novelty of the company's LNP technology and its potential to address the unmet needs of patients.

Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response

August 23, 2022

Proceedings of the National Academy of Sciences


Intracellular Delivery of Antibodies for Selective Cell Signaling Interference

March 18, 2022


In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery

February 14, 2022

ACS Biomaterials Science & Engineering

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis.

February 1, 2022

Proceedings of the National Academy of Sciences


In situ cancer vaccination using lipidoid nanoparticles

May 5, 2021

Science Advances

Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3

March 9, 2021

Proceedings of the National Academy of Sciences


Enhanced Protein Degradation by Intracellular Delivery of PreFused PROTACs Using Lipid-like Nanoparticles

November 21, 2020

Journal Citation Report (JCR) 

Imidazole-Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes

August 28, 2020

Angewandte Chemie

Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection

JULY 24, 2020

Science Advances

Combinatorial Library of Cyclic Benzylidene Acetal-Containing pHResponsive Lipidoid Nanoparticles for Intracellular mRNA Delivery

July 15, 2020

Bioconjugate Chemistry

Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles

June 15, 2020

Angewandte Chemie

Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo

March 6, 2020

Molecular Therapy Nucleic Acids

Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles

June 19, 2019

Advanced Materials

Combinatorial library of chalcogen-containing lipidoids for intracellular delivery of genome-editing proteins

March 8, 2018


Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles

February 20, 2014

Advanced Healthcare Materials

bottom of page